Kerri Fitzgerald

DocwireNews

CT-P10 is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. At the <a href="https://ash.confex.com/ash/2018/webprogram/Paper110334.html">2018 American Society of Hematology Annual Meeting</a>, and simultaneously published in <a href="https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30157-1/fulltext">The Lancet Haematology</a>, researchers reported that both agents were therapeutically equivalent and well-tolerated among patients with follicular lymphoma (FL).The ongoing, randomized, double-blind, parallel-group, active-controlled, phase III study compared the efficacy and safety between CT-P10 and rituximab as monotherapy in adult patients with newly diagnosed FL with stage II-IV, grade 1-3a, and low tumor burden disease. Between November 9, 2015, and January 4, 2018, 258 patients were randomized 1:1 to receive CT-P10 (n=130) or rituximab 375 mg/m2 intravenously (n=128) monotherapy weekly for four weeks as induction therapy. Patients who achieved complete response (CR), had unconfirmed CR, had partial response, or had stable disease after induction therapy went on to receive maintenance therapy every two months for two years. A total of 231 patients completed up to seven months of treatment: 119 (92%) of those receiving CT-P10 and 112 (88%) receiving rituximab.Over seven months, the overall response rate (ORR; primary endpoint) was 83.1% in the CT-P10 group and 81.3% in the rituximab group (treatment difference estimate = 1.8%; 90% confidence interval [CI] = &minus;6.43-10.20). Therapeutic equivalence was shown, as 90% CIs were within the prespecified margin of 17%, according to the authors.The study results indicated that CT-P10 was well tolerated, and both agents had a similar safety profile: The adverse event (AE) rate was 71% with CT-P10 and 67% with rituximab. Infections and infusion-related reactions occurred in a similar proportion of patients in both groups, and no patients experienced progressive multifocal leukoencephalopathy or hepatitis B virus reactivation.The most common grade 3 or 4 treatment-related AEs were decreased neutrophil count and neutropenia. Six (5%) patients receiving CT-P10 and three (2%) receiving rituximab experienced at least one treatment-related serious AE.&ldquo;CT-P10 monotherapy is suggested as a new therapeutic option for patients with low tumor burden FL,&rdquo; the authors concluded.

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Study Observes Equivalence Between CT-P10 Biosimilar and Reference Rituximab

Oncology

CT-P10 is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. At the 2018 American Society of Hematology Annual Meeting, and simultaneously ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe